Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Predictive Power of Artificial Intelligence for Malignant Cerebral Edema in Stroke Patients: A Ct-Based Systematic Review and Meta-Analysis of Prevalence and Diagnostic Performance Publisher Pubmed



Shafieioun A1 ; Ghaffari H2 ; Baradaran M3 ; Rigi A4 ; Shahir Eftekhar M5 ; Shojaeshafiei F6 ; Korani MA7 ; Hatami B6 ; Shirdel S8 ; Ghanbari K9 ; Ghaderi S10 ; Moharrami Yeganeh P11 ; Shahidi R12
Authors
Show Affiliations
Authors Affiliations
  1. 1. Rasa Medical Imaging and Therapy Center, Isfahan, Iran
  2. 2. Faculty of Medicine, Organ Transplant Super-Speciality Montaseriyeh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Department of Radiology, Imam Ali Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran
  4. 4. Department of Radiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Department of Surgery, School of Medicine, Qom University of Medical Sciences, Qom, Iran
  6. 6. Department of Radiology, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Radiology, Kermanshah University of Medical Sciences, Kermanshah, Iran
  8. 8. Department of Psychology, Faculty of Education and Psychology, University of Tabriz, Tabriz, Iran
  9. 9. Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  10. 10. Research Center for Evidence-Based Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
  11. 11. School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  12. 12. School of Medicine, Bushehr University of Medical Sciences, Moallem St, Bushehr County, Bushehr, 75146-33341, Iran

Source: Neurosurgical Review Published:2025


Abstract

Malignant cerebral edema (MCE) is a severe complication of acute ischemic stroke, with high mortality rates. Early and accurate prediction of MCE is critical for initiating timely interventions such as decompressive hemicraniectomy. Artificial intelligence (AI) and radiomics have emerged as promising tools for predicting MCE, offering the potential to transform reactive stroke management into proactive care. However, variability in methodologies and inconsistent reporting limits the widespread adoption of these technologies. A comprehensive search of PubMed, Embase, Web of Science, and Scopus identified studies reporting on the sensitivity, specificity, and area under the curve (AUC) of AI models in MCE prediction. Data were synthesized using random-effects meta-analyses. Subgroup analyses explored the impact of study design, machine learning input type, and other key factors on diagnostic accuracy. Publication bias was assessed using Egger’s test and funnel plot analyses. Data from ten studies encompassing 1,594 unique stroke patients were included in the analysis. The pooled sensitivity and specificity of AI models for predicting MCE were 81.1% (95% CI: 73.0–87.2%) and 92.6% (95% CI: 91.2–93.9%), respectively, with an AUC of 0.939. The diagnostic odds ratio was 43.73 (95% CI: 24.78–77.15), demonstrating excellent discriminative ability. Subgroup analyses revealed higher sensitivity and specificity in prospective studies (92.0% and 93.3%) compared to retrospective studies (76.1% and 91.4%). Radiomics-based models showed slightly higher sensitivity (84.2%) compared to non-radiomics models (80.4%), though both input types achieved comparable specificity. Interestingly, patients undergoing revascularization had a higher prevalence of MCE, likely due to their more severe initial presentations. Minimal heterogeneity was observed in specificity across studies, while publication bias was noted for sensitivity estimates. AI models show excellent diagnostic performance for predicting malignant cerebral edema (MCE), offering high sensitivity and specificity. Prospective studies, radiomics integration, and multi-center collaborations enhance their accuracy. However, external validation and standardized methodologies are needed to ensure broader clinical adoption and improve outcomes for stroke patients at risk of MCE. Clinical trial number Not applicable. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.